Cargando…
P1269: VIP152 IS A NOVEL CDK9 INHIBITOR WITH IMPROVED SELECTIVITY, TARGET MODULATION, AND CARDIAC SAFETY IN PATIENTS WITH LYMPHOMA
Autores principales: | Frigault, M., Sher, S., Ravikrishnan, J., Izumi, R., Ware, J., Wong, H., Johnson, A., Stelte-Ludwig, B., Byrd, J., Sampath, D., Rogers, K., Woyach, J., Lapalombella, R., Hamdy, A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430317/ http://dx.doi.org/10.1097/01.HS9.0000847940.03718.3d |
Ejemplares similares
-
VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia
por: Sher, Steven, et al.
Publicado: (2022) -
Enitociclib, a Selective CDK9 Inhibitor, Induces Complete Regression of MYC+ Lymphoma by Downregulation of RNA Polymerase II Mediated Transcription
por: Frigault, Melanie M., et al.
Publicado: (2023) -
Discovery of VIP236, an αvβ3-Targeted Small-Molecule–Drug Conjugate with Neutrophil Elastase-Mediated Activation of 7-Ethyl Camptothecin Payload for Treatment of Solid Tumors
por: Lerchen, Hans-Georg, et al.
Publicado: (2023) -
miR-1269a and miR-1269b: Emerging Carcinogenic Genes of the miR-1269 Family
por: Xie, Zijun, et al.
Publicado: (2022) -
HDAC1 regulates the chromatin landscape to control transcriptional dependencies in chronic lymphocytic leukemia
por: Lai, Tzung-Huei, et al.
Publicado: (2022)